Selected research
Industry Research
Interleukin Inhibitors for Psoriasis Industry Research Report 2026
Market perspective
The global Interleukin Inhibitors for Psoriasis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Interleukin Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Interleukin Inhibitors for Psoriasis is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Interleukin Inhibitors for Psoriasis is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Interleukin Inhibitors for Psoriasis include AbbVie Biotechnology, Almirall, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Samsung Bioepis, Sun Pharma and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Interleukin Inhibitors for Psoriasis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Interleukin Inhibitors for Psoriasis Market by Company
AbbVie Biotechnology
Almirall
Janssen Biotech
LEO Pharma
Novartis
Ortho Dermatologics
Samsung Bioepis
Sun Pharma
UCB
Dalian Yawei Pharmaceutical
China Medical System
Eli Lilly
Teva
Kyowa Kirin
Interleukin Inhibitors for Psoriasis Segment by Type
Interleukin-8 Inhibitors
Interleukin-23 Inhibitors
Interleukin-17 Inhibitors
Interleukin-12 Inhibitors
Other
Interleukin Inhibitors for Psoriasis Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Interleukin Inhibitors for Psoriasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Interleukin Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin Inhibitors for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Interleukin Inhibitors for Psoriasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Interleukin Inhibitors for Psoriasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Interleukin Inhibitors for Psoriasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Interleukin Inhibitors for Psoriasis Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Interleukin Inhibitors for Psoriasis Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Interleukin Inhibitors for Psoriasis Revenue of Manufacturers (2021-2026)
Table 9. Global Interleukin Inhibitors for Psoriasis Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Interleukin Inhibitors for Psoriasis Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Interleukin Inhibitors for Psoriasis Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Interleukin Inhibitors for Psoriasis, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Interleukin Inhibitors for Psoriasis, Product Type & Application
Table 14. Global Interleukin Inhibitors for Psoriasis Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Interleukin Inhibitors for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. AbbVie Biotechnology Company Information
Table 19. AbbVie Biotechnology Business Overview
Table 20. AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolio
Table 22. AbbVie Biotechnology Recent Developments
Table 23. Almirall Company Information
Table 24. Almirall Business Overview
Table 25. Almirall Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Almirall Interleukin Inhibitors for Psoriasis Product Portfolio
Table 27. Almirall Recent Developments
Table 28. Janssen Biotech Company Information
Table 29. Janssen Biotech Business Overview
Table 30. Janssen Biotech Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolio
Table 32. Janssen Biotech Recent Developments
Table 33. LEO Pharma Company Information
Table 34. LEO Pharma Business Overview
Table 35. LEO Pharma Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
Table 37. LEO Pharma Recent Developments
Table 38. Novartis Company Information
Table 39. Novartis Business Overview
Table 40. Novartis Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Novartis Interleukin Inhibitors for Psoriasis Product Portfolio
Table 42. Novartis Recent Developments
Table 43. Ortho Dermatologics Company Information
Table 44. Ortho Dermatologics Business Overview
Table 45. Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolio
Table 47. Ortho Dermatologics Recent Developments
Table 48. Samsung Bioepis Company Information
Table 49. Samsung Bioepis Business Overview
Table 50. Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolio
Table 52. Samsung Bioepis Recent Developments
Table 53. Sun Pharma Company Information
Table 54. Sun Pharma Business Overview
Table 55. Sun Pharma Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
Table 57. Sun Pharma Recent Developments
Table 58. UCB Company Information
Table 59. UCB Business Overview
Table 60. UCB Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. UCB Interleukin Inhibitors for Psoriasis Product Portfolio
Table 62. UCB Recent Developments
Table 63. Dalian Yawei Pharmaceutical Company Information
Table 64. Dalian Yawei Pharmaceutical Business Overview
Table 65. Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product Portfolio
Table 67. Dalian Yawei Pharmaceutical Recent Developments
Table 68. China Medical System Company Information
Table 69. China Medical System Business Overview
Table 70. China Medical System Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. China Medical System Interleukin Inhibitors for Psoriasis Product Portfolio
Table 72. China Medical System Recent Developments
Table 73. Eli Lilly Company Information
Table 74. Eli Lilly Business Overview
Table 75. Eli Lilly Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolio
Table 77. Eli Lilly Recent Developments
Table 78. Teva Company Information
Table 79. Teva Business Overview
Table 80. Teva Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Teva Interleukin Inhibitors for Psoriasis Product Portfolio
Table 82. Teva Recent Developments
Table 83. Kyowa Kirin Company Information
Table 84. Kyowa Kirin Business Overview
Table 85. Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolio
Table 87. Kyowa Kirin Recent Developments
Table 88. Global Interleukin Inhibitors for Psoriasis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 89. Global Interleukin Inhibitors for Psoriasis Sales by Region (2021-2026) & (K Units)
Table 90. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Region (2021-2026)
Table 91. Global Interleukin Inhibitors for Psoriasis Sales by Region (2027-2032) & (K Units)
Table 92. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Region (2027-2032)
Table 93. Global Interleukin Inhibitors for Psoriasis Revenue by Region (2021-2026) & (US$ Million)
Table 94. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Region (2021-2026)
Table 95. Global Interleukin Inhibitors for Psoriasis Revenue by Region (2027-2032) & (US$ Million)
Table 96. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Region (2027-2032)
Table 97. North America Interleukin Inhibitors for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 98. North America Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 99. North America Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units)
Table 100. North America Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2026) & (US$ Million)
Table 101. North America Interleukin Inhibitors for Psoriasis Revenue by Country (2027-2032) & (US$ Million)
Table 102. Europe Interleukin Inhibitors for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 103. Europe Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 104. Europe Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units)
Table 105. Europe Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2026) & (US$ Million)
Table 106. Europe Interleukin Inhibitors for Psoriasis Revenue by Country (2027-2032) & (US$ Million)
Table 107. Asia Pacific Interleukin Inhibitors for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 109. Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units)
Table 110. Asia Pacific Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2026) & (US$ Million)
Table 111. Asia Pacific Interleukin Inhibitors for Psoriasis Revenue by Country (2027-2032) & (US$ Million)
Table 112. South America Interleukin Inhibitors for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. South America Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 114. South America Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units)
Table 115. South America Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2026) & (US$ Million)
Table 116. South America Interleukin Inhibitors for Psoriasis Revenue by Country (2027-2032) & (US$ Million)
Table 117. Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 118. Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2021-2026) & (K Units)
Table 119. Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2027-2032) & (K Units)
Table 120. Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2026) & (US$ Million)
Table 121. Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue by Country (2027-2032) & (US$ Million)
Table 122. Global Interleukin Inhibitors for Psoriasis Sales by Type (2021-2026) & (K Units)
Table 123. Global Interleukin Inhibitors for Psoriasis Sales by Type (2027-2032) & (K Units)
Table 124. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2021-2026)
Table 125. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2027-2032)
Table 126. Global Interleukin Inhibitors for Psoriasis Revenue by Type (2021-2026) & (US$ Million)
Table 127. Global Interleukin Inhibitors for Psoriasis Revenue by Type (2027-2032) & (US$ Million)
Table 128. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2021-2026)
Table 129. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2027-2032)
Table 130. Global Interleukin Inhibitors for Psoriasis Price by Type (2021-2026) & (US$/Unit)
Table 131. Global Interleukin Inhibitors for Psoriasis Price by Type (2027-2032) & (US$/Unit)
Table 132. Global Interleukin Inhibitors for Psoriasis Sales by Application (2021-2026) & (K Units)
Table 133. Global Interleukin Inhibitors for Psoriasis Sales by Application (2027-2032) & (K Units)
Table 134. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2021-2026)
Table 135. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2027-2032)
Table 136. Global Interleukin Inhibitors for Psoriasis Revenue by Application (2021-2026) & (US$ Million)
Table 137. Global Interleukin Inhibitors for Psoriasis Revenue by Application (2027-2032) & (US$ Million)
Table 138. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2021-2026)
Table 139. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2027-2032)
Table 140. Global Interleukin Inhibitors for Psoriasis Price by Application (2021-2026) & (US$/Unit)
Table 141. Global Interleukin Inhibitors for Psoriasis Price by Application (2027-2032) & (US$/Unit)
Table 142. Key Raw Materials
Table 143. Raw Materials Key Suppliers
Table 144. Interleukin Inhibitors for Psoriasis Distributors List
Table 145. Interleukin Inhibitors for Psoriasis Customers List
Table 146. Interleukin Inhibitors for Psoriasis Industry Trends
Table 147. Interleukin Inhibitors for Psoriasis Industry Drivers
Table 148. Interleukin Inhibitors for Psoriasis Industry Restraints
Table 149. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Interleukin Inhibitors for Psoriasis Product Image
Figure 5. Global Interleukin Inhibitors for Psoriasis Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Interleukin Inhibitors for Psoriasis Market Size (2021-2032) & (US$ Million)
Figure 7. Global Interleukin Inhibitors for Psoriasis Sales (2021-2032) & (K Units)
Figure 8. Global Interleukin Inhibitors for Psoriasis Average Price (US$/Unit) & (2021-2032)
Figure 9. Interleukin-8 Inhibitors Product Image
Figure 10. Interleukin-23 Inhibitors Product Image
Figure 11. Interleukin-17 Inhibitors Product Image
Figure 12. Interleukin-12 Inhibitors Product Image
Figure 13. Other Product Image
Figure 14. Hospital and Clinic Product Image
Figure 15. Retail Pharmacies Product Image
Figure 16. Other Product Image
Figure 17. Global Interleukin Inhibitors for Psoriasis Revenue Share by Manufacturers in 2025
Figure 18. Global Manufacturers of Interleukin Inhibitors for Psoriasis, Manufacturing Sites & Headquarters
Figure 19. Global Top 5 and 10 Interleukin Inhibitors for Psoriasis Players Market Share by Revenue in 2025
Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. Global Interleukin Inhibitors for Psoriasis Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 22. Global Interleukin Inhibitors for Psoriasis Sales by Region in 2025
Figure 23. Global Interleukin Inhibitors for Psoriasis Revenue by Region in 2025
Figure 24. North America Interleukin Inhibitors for Psoriasis Market Size by Country in 2025
Figure 25. North America Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032)
Figure 26. North America Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2021-2032)
Figure 27. United States Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Canada Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Mexico Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. Europe Interleukin Inhibitors for Psoriasis Market Size by Country in 2025
Figure 31. Europe Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032)
Figure 32. Europe Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2021-2032)
Figure 33. Germany Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. France Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. U.K. Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Italy Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Russia Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Spain Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Netherlands Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Switzerland Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Sweden Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Poland Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Asia Pacific Interleukin Inhibitors for Psoriasis Market Size by Country in 2025
Figure 44. Asia Pacific Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032)
Figure 45. Asia Pacific Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2021-2032)
Figure 46. China Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. Japan Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. South Korea Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. India Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Australia Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Taiwan Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Southeast Asia Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Southeast Asia Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. South America Interleukin Inhibitors for Psoriasis Market Size by Country in 2025
Figure 55. South America Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032)
Figure 56. South America Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2021-2032)
Figure 57. Brazil Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Argentina Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Chile Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Middle East and Africa Interleukin Inhibitors for Psoriasis Market Size by Country in 2025
Figure 61. Middle East and Africa Interleukin Inhibitors for Psoriasis Sales Market Share by Country (2021-2032)
Figure 62. Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue Market Share by Country (2021-2032)
Figure 63. Egypt Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 64. South Africa Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. Israel Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. Türkiye Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. GCC Countries Interleukin Inhibitors for Psoriasis Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 68. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2021-2032)
Figure 69. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032)
Figure 70. Global Interleukin Inhibitors for Psoriasis Price (US$/Unit) by Type (2021-2032)
Figure 71. Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2021-2032)
Figure 72. Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032)
Figure 73. Global Interleukin Inhibitors for Psoriasis Price (US$/Unit) by Application (2021-2032)
Figure 74. Interleukin Inhibitors for Psoriasis Value Chain
Figure 75. Interleukin Inhibitors for Psoriasis Production Mode & Process
Figure 76. Direct Comparison with Distribution Share
Figure 77. Distributors Profiles
Figure 78. Interleukin Inhibitors for Psoriasis Industry Opportunities and Challenges
Scope & coverage.
Types
- Interleukin-8 Inhibitors
- Interleukin-23 Inhibitors
- Interleukin-17 Inhibitors
- Interleukin-12 Inhibitors
- Other
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- AbbVie Biotechnology
- Almirall
- Janssen Biotech
- LEO Pharma
- Novartis
- Ortho Dermatologics
- Samsung Bioepis
- Sun Pharma
- UCB
- Dalian Yawei Pharmaceutical
- China Medical System
- Eli Lilly
- Teva
- Kyowa Kirin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Interleukin Inhibitors for Psoriasis Market Size (2021-2032)
- 2.2.2 Global Interleukin Inhibitors for Psoriasis Sales (2021-2032)
- 2.2.3 Global Interleukin Inhibitors for Psoriasis Market Average Price (2021-2032)
- 2.3 Interleukin Inhibitors for Psoriasis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Interleukin-8 Inhibitors
- 2.3.3 Interleukin-23 Inhibitors
- 2.3.4 Interleukin-17 Inhibitors
- 2.3.5 Interleukin-12 Inhibitors
- 2.3.6 Other
- 2.4 Interleukin Inhibitors for Psoriasis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Retail Pharmacies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Interleukin Inhibitors for Psoriasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Interleukin Inhibitors for Psoriasis Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Interleukin Inhibitors for Psoriasis Revenue of Manufacturers (2021-2026)
- 3.4 Global Interleukin Inhibitors for Psoriasis Average Price by Manufacturers (2021-2026)
- 3.5 Global Interleukin Inhibitors for Psoriasis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Interleukin Inhibitors for Psoriasis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Interleukin Inhibitors for Psoriasis, Product Type & Application
- 3.8 Global Manufacturers of Interleukin Inhibitors for Psoriasis, Established Date
- 3.9 Global Interleukin Inhibitors for Psoriasis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 AbbVie Biotechnology
- 4.1.1 AbbVie Biotechnology Company Information
- 4.1.2 AbbVie Biotechnology Business Overview
- 4.1.3 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 AbbVie Biotechnology Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.1.5 AbbVie Biotechnology Recent Developments
- 4.2 Almirall
- 4.2.1 Almirall Company Information
- 4.2.2 Almirall Business Overview
- 4.2.3 Almirall Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Almirall Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.2.5 Almirall Recent Developments
- 4.3 Janssen Biotech
- 4.3.1 Janssen Biotech Company Information
- 4.3.2 Janssen Biotech Business Overview
- 4.3.3 Janssen Biotech Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Janssen Biotech Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.3.5 Janssen Biotech Recent Developments
- 4.4 LEO Pharma
- 4.4.1 LEO Pharma Company Information
- 4.4.2 LEO Pharma Business Overview
- 4.4.3 LEO Pharma Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 LEO Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.4.5 LEO Pharma Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Ortho Dermatologics
- 4.6.1 Ortho Dermatologics Company Information
- 4.6.2 Ortho Dermatologics Business Overview
- 4.6.3 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ortho Dermatologics Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.6.5 Ortho Dermatologics Recent Developments
- 4.7 Samsung Bioepis
- 4.7.1 Samsung Bioepis Company Information
- 4.7.2 Samsung Bioepis Business Overview
- 4.7.3 Samsung Bioepis Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Samsung Bioepis Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.7.5 Samsung Bioepis Recent Developments
- 4.8 Sun Pharma
- 4.8.1 Sun Pharma Company Information
- 4.8.2 Sun Pharma Business Overview
- 4.8.3 Sun Pharma Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sun Pharma Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.8.5 Sun Pharma Recent Developments
- 4.9 UCB
- 4.9.1 UCB Company Information
- 4.9.2 UCB Business Overview
- 4.9.3 UCB Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 UCB Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.9.5 UCB Recent Developments
- 4.10 Dalian Yawei Pharmaceutical
- 4.10.1 Dalian Yawei Pharmaceutical Company Information
- 4.10.2 Dalian Yawei Pharmaceutical Business Overview
- 4.10.3 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Dalian Yawei Pharmaceutical Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.10.5 Dalian Yawei Pharmaceutical Recent Developments
- 4.11 China Medical System
- 4.11.1 China Medical System Company Information
- 4.11.2 China Medical System Business Overview
- 4.11.3 China Medical System Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 China Medical System Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.11.5 China Medical System Recent Developments
- 4.12 Eli Lilly
- 4.12.1 Eli Lilly Company Information
- 4.12.2 Eli Lilly Business Overview
- 4.12.3 Eli Lilly Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Eli Lilly Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.12.5 Eli Lilly Recent Developments
- 4.13 Teva
- 4.13.1 Teva Company Information
- 4.13.2 Teva Business Overview
- 4.13.3 Teva Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Teva Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.13.5 Teva Recent Developments
- 4.14 Kyowa Kirin
- 4.14.1 Kyowa Kirin Company Information
- 4.14.2 Kyowa Kirin Business Overview
- 4.14.3 Kyowa Kirin Interleukin Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Kyowa Kirin Interleukin Inhibitors for Psoriasis Product Portfolio
- 4.14.5 Kyowa Kirin Recent Developments
5 Global Interleukin Inhibitors for Psoriasis Market Scenario by Region
- 5.1 Global Interleukin Inhibitors for Psoriasis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2021-2032
- 5.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2021-2026
- 5.2.2 Global Interleukin Inhibitors for Psoriasis Sales by Region: 2027-2032
- 5.3 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2021-2032
- 5.3.1 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2021-2026
- 5.3.2 Global Interleukin Inhibitors for Psoriasis Revenue by Region: 2027-2032
- 5.4 North America Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
- 5.4.1 North America Interleukin Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
- 5.4.3 North America Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
- 5.5.1 Europe Interleukin Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
- 5.5.3 Europe Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Interleukin Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
- 5.7.1 South America Interleukin Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
- 5.7.3 South America Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Interleukin Inhibitors for Psoriasis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Interleukin Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Interleukin Inhibitors for Psoriasis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Interleukin Inhibitors for Psoriasis Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2021-2032)
- 6.1.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Type (2021-2032)
- 6.2 Global Interleukin Inhibitors for Psoriasis Revenue by Type (2021-2032)
- 6.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Type (2021-2032)
- 6.3 Global Interleukin Inhibitors for Psoriasis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2021-2032)
- 7.1.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Interleukin Inhibitors for Psoriasis Sales Market Share by Application (2021-2032)
- 7.2 Global Interleukin Inhibitors for Psoriasis Revenue by Application (2021-2032)
- 7.2.1 Global Interleukin Inhibitors for Psoriasis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Interleukin Inhibitors for Psoriasis Revenue Market Share by Application (2021-2032)
- 7.3 Global Interleukin Inhibitors for Psoriasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Interleukin Inhibitors for Psoriasis Value Chain Analysis
- 8.1.1 Interleukin Inhibitors for Psoriasis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Interleukin Inhibitors for Psoriasis Production Mode & Process
- 8.2 Interleukin Inhibitors for Psoriasis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Interleukin Inhibitors for Psoriasis Distributors
- 8.2.3 Interleukin Inhibitors for Psoriasis Customers
9 Global Interleukin Inhibitors for Psoriasis Analyzing Market Dynamics
- 9.1 Interleukin Inhibitors for Psoriasis Industry Trends
- 9.2 Interleukin Inhibitors for Psoriasis Industry Drivers
- 9.3 Interleukin Inhibitors for Psoriasis Industry Opportunities and Challenges
- 9.4 Interleukin Inhibitors for Psoriasis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst